Dr. Turtle completed medical training in Australia, followed by dual Fellowships of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia, and a PhD in Immunology. He is an Associate Member at Fred Hutchinson Cancer Research Center (FHCRC) and Associate Professor at the University of Washington (UW) in Seattle, WA. He serves as an attending physician on the Hematopoietic Stem Cell Transplant (HCT) Service and the Immunotherapy Service at FHCRC, Seattle Cancer Care Alliance (SCCA) and the UW Medical Center, and has a research laboratory in the Clinical Research Division at FHCRC. His laboratory is focused on understanding the characteristics of distinct subsets of human CD8+ T cells, their potential utility for tumor immunotherapy, and their role in immune reconstitution after HCT. Dr. Turtle is Principal Investigator and IND sponsor of several investigator-initiated clinical trials of CD19-targeted chimeric antigen receptor (CAR)-modified T cell therapy for patients with B cell malignancies.
Cameron J. Turtle, MBBS, PhD